Acceleron Pharma

In early 2011, clinical trials of ACE-031, a myostatin inhibitor, were halted pending resolution of safety issues; in May 2013, the developers discontinued work on the drug

posted on May 2, 2013 - 12:00pm
posted on March 31, 2011 - 11:41am
QUEST Vol. 18, No. 2
When John Knopf co-founded Acceleron Pharma in the spring of 2003, a muscle protein called myostatin had been on his and other researchers’ radar for several years. The protein had been identified as a “negative regulator” (limiter) of muscle growth and regeneration back in 1997. And, since that time, myostatin-deficient mice and cattle had been shown to have large, strong muscles without...